Novozymes has acquired Delta Biotechnology Ltd from the sanofi-aventis group. Established in 1984, Delta is, from 6th July, a wholly-owned subsidiary of Novozymes A/S operating as a self-contained business unit with both its R&D and manufacturing facilities based in Nottingham, UK. The new company will operate under the name Novozymes Delta Ltd.
BioSpace
Simplifying Global Compliance
Recommended Products
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.
Biological Risk Evaluation and Management for Medical Devices
Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.
Editor's Picks
Zimmer Biomet’s 3D Printed Titanium Spinal Implant Receives 510(k) Clearance
The system includes surgical tools to insert, move and remove the implants.
Senate Subcommittee Advances $5.4 Billion FDA Spending Bill
The full Senate appropriations committee will consider the bill on Thursday.
FDAnews Drug Daily Bulletin
NOVOZYMES, INC. ACQUIRES DELTA BIOTECHNOLOGY, LTD.
July 11, 2006